SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: M. Boldo who wrote (391)4/14/1998 1:24:00 PM
From: RBMac  Read Replies (1) | Respond to of 1185
 
NORTRAN PHARMACEUTICALS INC. ANNOUNCES RSD921 CLINICAL TRIAL UPDATE

Here's some news....

VANCOUVER, April 14 /CNW/ - Nortran Pharmaceuticals Inc.
VSE: NRT
NASDQ: NTRDF

Nortran Pharmaceuticals Inc. is pleased to announce continuing progress
in preparing its local anaesthetic, RSD921, for Phase II clinical trials in
Malaysia in association with its partner, the Chemical Company of Malaysia
(CCM). The development timetable calls for the Phase II trials to begin in
the period late May to early June.
A clinical trials batch of RSD921 has been synthesized and is currently
being prepared for formulation. The clinical trial site and investigators
have been confirmed at the University of Malaysia, Kuala Lumpur, Malaysia, and
the necessary ethical approvals have been granted. CCM has filed with the
Malaysian Ministry of Health for government approval to import and use RSD921
in the above clinical trials. Governmental approval is expected within the
next four weeks.
Mr. Bob Rieder assumes the role of President and Chief Executive Officer
on April 16, 1998.
Nortran Pharmaceuticals is a drug discovery company whose focus is
pathology targeted small molecules. Nortran's current drugs in development
target the ion channels responsible for life-threatening arrhythmias of the
heart and for intractable pain.

ON BEHALF OF THE BOARD

Michael J. A. Walker, Ph.D.
Chairman

THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT
RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.
%SEDAR: 00003146



To: M. Boldo who wrote (391)4/21/1998 12:42:00 AM
From: Wisee  Read Replies (1) | Respond to of 1185
 
Michael,

Where are you??? Any new insights into NRT???

As you previously indicated, in three years time, it would be nice to see Nortran's EPS from royalties be larger than the share price now?? At 15 times EPS, Nortran would be >$30. It's hard to imagine, but as Allen B. stated "don't underestimate Nortran!!"

Wisee


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News